Journals / Türk Oftalmoloji Dergisi / 2012 / Cilt: 42 - Sayı: 6

Uveitis related with multiple sclerosis

Multipl skleroz ile ilişkili üveitler

Pages
462–465
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Discussion: Uveitis can be taken under control and recurrences and permanent visual loss can be prevented in patients treated with interferon β-1a.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the clinical findings and outcomes of uveitis in patients with multiple sclerosis (MS).
📊
Key Findings & Data:Material and Method: We retrospectively evaluated the medical records of eight MS patients who had presented with uveitis to the uveitis clinic between years 2005 and 2011.
💡
Conclusion & Impact:Discussion: Uveitis can be taken under control and recurrences and permanent visual loss can be prevented in patients treated with interferon β-1a.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the clinical findings and outcomes of uveitis in patients with multiple sclerosis (MS). Material and Method: We retrospectively evaluated the medical records of eight MS patients who had presented with uveitis to the uveitis clinic between years 2005 and 2011. Results: The mean visual acuity of the thirteen eyes of eight patients (seven women, one man; mean age 39±7.5 years; mean follow-up 3.8±1.8 years) was 0.7±0.2 at the time of presentation. Two patients were diagnosed as anterior uveitis related with MS, five patients as intermediate uveitis and retinal vasculitis, and one patient as retinal vasculitis alone. All patients received interferon β-1a during the follow-up. The uveitis treatment was applied according to the localization of the disease. Except in one, the visual acuity was restored in all patients at the end of follow-up. Discussion: Uveitis can be taken under control and recurrences and permanent visual loss can be prevented in patients treated with interferon β-1a.

Özet

Amaç: Multipl sklerozlu (MS) hastalarda gelişen üveitin klinik bulgularını ve sonuçlarını değerlendirmek. Gereç ve Yöntem: 2005-2011 yılları arasında üveit polikliniğine başvuran multipl sklerozu ve üveiti olan sekiz hastanın kayıtları retrospektif olarak incelendi. Sonuçlar: Başvuru sırasında sekiz hastanın (Yedi kadın, bir erkek; ortalama yaş 39±7,5 yıl; ortalama izlem süresi 3,8±1,8 yıl) on üç gözünün ortalama görme keskinliği 0,7±0,2 idi. İki hastaya MS ile ilişkili ön üveit, beş hastaya intermedier üveit ve retinal vaskülit, bir hastaya retinal vaskülit tanısı konuldu. Takip boyunca tüm hastalar interferon β-1a tedavisi altındaydı. Hastaların üveit tedavileri hastalığın lokalizasyonuna göre yapıldı. Takip sonunda bir olgu dışında tüm hastaların görme keskinliği tam olarak korundu. Tart›flma: Sistemik interferon β-1a uygulanan hastalarda üveit tedavi ile kontrol altına alınabilmekte, sık rekürrensler ve kalıcı görme kayıpları önlenebilmektedir.

🔖

Cite This Article

GÜNGÖR, S. G., AYDIN, Y. A., AKAR, E. (2022). Uveitis related with multiple sclerosis. Türk Oftalmoloji Dergisi, Cilt: 42 - Sayı: 6, 462–465. https://ajindex.com/articles/638244

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Schmidt S, Wessels L, Augustin A, Klockgether T. Patients with multiple sclerosis and concomitant uveitis/periphlebitis retinae are not distinct from those without intraocular inflammation. J Neurol Sci. 2001;187:49-53
  2. Rucker CW. Sheathing of the retinal veins in multiple sclerosis. Review of pertinent literature. Mayo Clin Proc. 1972;47:335-40
  3. Acar MA, Birch MK, Abbott R, Rosenthal AR. Chronic granulomatous anterior uveitis associated with multiple sclerosis. Graefes Arch Clin Exp Ophthalmol. 1993;231:166-8
  4. Biousse V, Trichet C, Bloch-Michel E, Roullet E. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology. 1999;52:179-81
  5. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-31
  6. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993;100:818-24
  7. Schmidt S, Wessels L, Augustin A, Klockgether T. Patients with multiple sclerosis and concomitant uveitis/periphlebitis retinae are not distinct from those without intraocular inflammation. J Neurol Sci. 2001;187:49-53
  8. Graham EM, Francis DA, Sanders MD, Rudge P. Ocular inflammatory changes in established multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989;52:1360-63
  9. Lightman S, McDonald WI, Bird AC, et al. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987;110:405-14
  10. Yılmaz T, Yıldırım S, Aydemir O, Çelebi S, Kükner AŞ. Multiple sklerozisli bir olguda retina periflebiti ve üveit. Ret-Vit. 2003;11(Supll):41-5
  11. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1.Clinical effects. J Neurol Neurosurg Psychiatry. 1987;50:511-6
  12. Hommes OR, Barkhof F, Jongen PJ, Frequin ST. Methylprednisolone treatment in multiple sclerosis: effect of treatment, pharmacokinetics, future. Mult Scler. 1996;1:327-8
  13. Spoor TC, Rockwell DL. Treatment of optic neuritis with intravenous megadose corticosteroids. A consecutive series. Ophthalmology. 1988;95:131-4
  14. Wakefield D, Jennings A, McCluskey PJ. Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis. Clin Experiment Ophthalmol. 2000;28:103-6
  15. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS. Neurology. 2001;56:1628-36. 1